Home > Insider Trading > Filing (0001516551-23-000069)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1516551	Skye Bioscience Inc.	SKYE	()	4/A

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1425052	Punit Dhillon	11250 El Camino Real, Suite 100 C/O Skye Bioscience, Inc. San Diego CA 92130	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-08-25	20,277,414	$0.00	24,683,957	No	4	A	Direct
Common Stock	Acquisiton	2023-08-23	9,000	$0.01	24,692,957	No	4	L	Direct
Common Stock	Acquisiton	2023-08-28	110,000	$0.02	24,802,957	No	4	L	Direct
Common Stock	Acquisiton	2023-08-29	881,000	$0.02	25,683,957	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	L	Direct
No	4	L	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2023-08-25	2,253,046	$0.00	2,253,046	$0.01

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2,253,046		2033-08-25	No	4	A	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	2,335,721	Indirect	Trust

Footnotes

Represents a restricted stock unit ("RSU") award that vests on the following performance milestones : 25% vests upon achieving a market cap of $125M, an additional 25% vests upon achieving a market cap of $250M, an additional 25% vests upon achieving a market cap of $400M, an additional 25% vest at an exit of $500M or greater; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs . Notwithstanding anything to the foregoing, all of the RSUS shall vest if an exit greater than $500M is achieved at an earlier date.
Each RSU represents a contingent right to receive one share of the Issuer's common stock.
The shares are held by a trust for which the Reporting Person is a trustee and has voting and dispositive power over the shares.
The option grant shall be exercisable for a price of $0.014 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the four year period beginning August 24, 2023. Upon a change in control of the Issuer, 100% of the options will become fully vested.